CoChat

Combined Administration of (R)-Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Induces Rapid and Sustained Effects in the CUMS Model of Depression via a TrkB/BDNF-Dependent Mechanism

Open access

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

Abstract

Ketamine is an effective, rapid-acting antidepressant drug (RAAD), but it induces side effects. To overcome these challenges, attempts have been made to use safer enantiomer ((R)-ketamine) or mGlu2/3 receptor antagonists, which induce ketamine-like effects and enhance its action. Here, we propose combining these two strategies to investigate the antidepressant-like effects of low doses of two ketamine enantiomers in combination with a low dose of the mGlu2/3 receptor antagonist LY341495. Rapid and sustained antidepressant-like effects were assessed in C57BL/6J mice using the tail suspension test (TST) and the chronic unpredictable mild stress (CUMS) model of depression in stress-naïve mice. ELISA was used to measure BDNF levels. In the TST, low doses of both (S)-ketamine and (R)-ketamine were potentiated by a subeffective dose of LY341495. However, in the CUMS model, only (R)-ketamine was able to induce long-lasting anti-apathetic and anti-anhedonic effects when coadministered with low-dose LY341495. The mechanism of this drug combination was dependent on BDNF and AMPA receptor activity. ELISA results suggest that the hippocampus might be the site of this action. MGlu2/3 receptor antagonists, in combination with (R)-ketamine, may serve as potential RAADs, with a high efficiency and low risk of side effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph15020125

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The antidepressant-like effects of (S)-ketamine (blue panel) and (R)-ketamine (green panel) coadministered with LY341495 in the TST. (A) schedule of experiments B and C; (B) the antidepressant-like effects of (S)-ketamine coadministered with LY341495; (C) the antidepressant-like effects of (R)-ketamine coadministered with LY341495; (D) schedule of experiments E and F; (E) influence of NBQX on the antidepressant-like effect of the mix SL; (F) influence of NBQX on the antidepressant-like effect of the mix RL; (G) schedule of experiments H and I; (H) influence of ANA-12 on the antidepressant-like effect of the mix SL; (I) influence of ANA-12 on the antidepressant-like effect of the mix RL; (J) schedule of experiments K and L; (K) influence of LY379268 on the antidepressant-like effect of the mix SL; (L) influence of LY379268 on the antidepressant-like effect of the mix RL. The values are expressed as the means ± SEM and were analyzed by two-way ANOVA. * p < 0.05, ** p < 0.01 drug × drug interaction; **** p < 0.0001 mix SL or mix RL main effect; @ p < 0.05 drug × drug interaction (N = 8–9). Mix SL—(S)-ketamine 1 mg/kg + LY 341495 0.1 mg/kg; mix RL—(R)-ketamine 1 mg/kg + LY 341495 0.1 mg/kg.
Figure 1 The antidepressant-like effects of (S)-ketamine (blue panel) and (R)-ketamine (green panel) coadministered with LY341495 in the TST. (A) schedule of experiments B and C; (B) the antidepressant-like effects of (S)-ketamine coadministered with LY341495; (C) the antidepressant-like effects of (R)-ketamine coadministered with LY341495; (D) schedule of experiments E and F; (E) influence of NBQX on the antidepressant-like effect of the mix SL; (F) influence of NBQX on the antidepressant-like effect of the mix RL; (G) schedule of experiments H and I; (H) influence of ANA-12 on the antidepressant-like effect of the mix SL; (I) influence of ANA-12 on the antidepressant-like effect of the mix RL; (J) schedule of experiments K and L; (K) influence of LY379268 on the antidepressant-like effect of the mix SL; (L) influence of LY379268 on the antidepressant-like effect of the mix RL. The values are expressed as the means ± SEM and were analyzed by two-way ANOVA. * p < 0.05, ** p < 0.01 drug × drug interaction; **** p < 0.0001 mix SL or mix RL main effect; @ p < 0.05 drug × drug interaction (N = 8–9). Mix SL—(S)-ketamine 1 mg/kg + LY 341495 0.1 mg/kg; mix RL—(R)-ketamine 1 mg/kg + LY 341495 0.1 mg/kg.CC BY · PubMed Central
Figure 2 The antidepressant-like effects of (S)-ketamine (blue panel) and (R)-ketamine (green panel) in the CUMS model of depression. (A) schedule of experiments B and C; (B) (S)-ketamine effect in the splash test; (C) (R)-ketamine effect in the splash test; (D) schedule of experiments E and F; (E) (S)-ketamine effect in the sucrose preference test; (F) (R)-ketamine effect in the sucrose preference test; (G) schedule of experiments H and I; (H) (S)-ketamine effect in the TST; (I) (R)-ketamine effect in the TST. The values are expressed as the means ± SEM and were analyzed by two-way ANOVA. @ p < 0.05, @@ p < 0.01, @@@ p < 0.001 CUMS × drug interaction; * p < 0.05, *** p < 0.001, **** p < 0.0001 (CUMS effect, t-test) (N = 10–12).
Figure 2 The antidepressant-like effects of (S)-ketamine (blue panel) and (R)-ketamine (green panel) in the CUMS model of depression. (A) schedule of experiments B and C; (B) (S)-ketamine effect in the splash test; (C) (R)-ketamine effect in the splash test; (D) schedule of experiments E and F; (E) (S)-ketamine effect in the sucrose preference test; (F) (R)-ketamine effect in the sucrose preference test; (G) schedule of experiments H and I; (H) (S)-ketamine effect in the TST; (I) (R)-ketamine effect in the TST. The values are expressed as the means ± SEM and were analyzed by two-way ANOVA. @ p < 0.05, @@ p < 0.01, @@@ p < 0.001 CUMS × drug interaction; * p < 0.05, *** p < 0.001, **** p < 0.0001 (CUMS effect, t-test) (N = 10–12).CC BY · PubMed Central
Figure 3 The effects of (S)-ketamine (blue panel) and (R)-ketamine (green panel) coadministered with LY341495 in the CUMS model of depression. (A) schedule of experiments B and C; (B) effects of (S)-ketamine coadministered with LY341495 in the splash test; (C) effects of (R)-ketamine coadministered with LY341495 in the splash test; (D) schedule of experiments E and F; (E) effects of (S)-ketamine coadministered with LY341495 in the sucrose preference test; (F) effects of (R)-ketamine coadministered with LY341495 in the sucrose preference test; (G) schedule of experiments H and I; (H) effects of (S)-ketamine coadministered with LY341495 in the TST; (I) effects of (R)-ketamine coadministered with LY341495 in the TST. The values are expressed as the means ± SEM and were analyzed by two-way ANOVA. @ p < 0.05, @@ p < 0.01, @@@ p < 0.001 drug × drug interaction; ** p < 0.01, *** p < 0.001, **** p < 0.0001 (CUMS effect, t-test) (N = 10–12).
Figure 3 The effects of (S)-ketamine (blue panel) and (R)-ketamine (green panel) coadministered with LY341495 in the CUMS model of depression. (A) schedule of experiments B and C; (B) effects of (S)-ketamine coadministered with LY341495 in the splash test; (C) effects of (R)-ketamine coadministered with LY341495 in the splash test; (D) schedule of experiments E and F; (E) effects of (S)-ketamine coadministered with LY341495 in the sucrose preference test; (F) effects of (R)-ketamine coadministered with LY341495 in the sucrose preference test; (G) schedule of experiments H and I; (H) effects of (S)-ketamine coadministered with LY341495 in the TST; (I) effects of (R)-ketamine coadministered with LY341495 in the TST. The values are expressed as the means ± SEM and were analyzed by two-way ANOVA. @ p < 0.05, @@ p < 0.01, @@@ p < 0.001 drug × drug interaction; ** p < 0.01, *** p < 0.001, **** p < 0.0001 (CUMS effect, t-test) (N = 10–12).CC BY · PubMed Central
Figure 4 Sustained effects of (R)-ketamine coadministered with LY341495 in the CUMS model of depression. (A) schedule of experiment and effects in the splash test; (B) schedule of experiment and effects in the sucrose preference test; (C) schedule of experiment and effects in the TST. The values are expressed as the means ± SEM and were analyzed by two-way ANOVA. @ p < 0.05, @@ p < 0.01 drug × drug interaction; * p < 0.05, *** p < 0.001, **** p < 0.0001 (CUMS effect, t-test) (N = 10–12).
Figure 4 Sustained effects of (R)-ketamine coadministered with LY341495 in the CUMS model of depression. (A) schedule of experiment and effects in the splash test; (B) schedule of experiment and effects in the sucrose preference test; (C) schedule of experiment and effects in the TST. The values are expressed as the means ± SEM and were analyzed by two-way ANOVA. @ p < 0.05, @@ p < 0.01 drug × drug interaction; * p < 0.05, *** p < 0.001, **** p < 0.0001 (CUMS effect, t-test) (N = 10–12).CC BY · PubMed Central
Figure 5 Mechanisms of the effects of (R)-ketamine coadministered with LY341495 in the CUMS model of depression. (A) schedule of experiments and effects of NBQX or ANA-12 pretreatment on the antidepressant-like effects of the mix RL in the splash test; (B) schedule of experiments and effects of NBQX or ANA-12 pretreatment on the antidepressant-like effects of the mix RL in the sucrose preference test; (C) schedule of experiments and effects of NBQX or ANA-12 pretreatment on the antidepressant-like effects of the mix RL in the TST. The values are expressed as the means ± SEM and were analyzed by two-way ANOVA. @ p < 0.05, @@ p < 0.01, @@@ p < 0.001 drug × drug interaction; ## p < 0.01, #### p < 0.0001 mix RL main effect; * p < 0.05, **** p < 0.0001 (CUMS effect, t test) (N = 10–12). Mix RL–(R)-ketamine 1 mg/kg + LY 341495 0.3 mg/kg.
Figure 5 Mechanisms of the effects of (R)-ketamine coadministered with LY341495 in the CUMS model of depression. (A) schedule of experiments and effects of NBQX or ANA-12 pretreatment on the antidepressant-like effects of the mix RL in the splash test; (B) schedule of experiments and effects of NBQX or ANA-12 pretreatment on the antidepressant-like effects of the mix RL in the sucrose preference test; (C) schedule of experiments and effects of NBQX or ANA-12 pretreatment on the antidepressant-like effects of the mix RL in the TST. The values are expressed as the means ± SEM and were analyzed by two-way ANOVA. @ p < 0.05, @@ p < 0.01, @@@ p < 0.001 drug × drug interaction; ## p < 0.01, #### p < 0.0001 mix RL main effect; * p < 0.05, **** p < 0.0001 (CUMS effect, t test) (N = 10–12). Mix RL–(R)-ketamine 1 mg/kg + LY 341495 0.3 mg/kg.CC BY · PubMed Central
Figure 6 The effects of (S)-ketamine and (R)-ketamine coadministered with LY341495 on the locomotor activity of mice. The values are expressed as the means ± SEM and were analyzed by repeated-measures ANOVA. **** p < 0.0001 vs. vehicle (N = 8).
Figure 6 The effects of (S)-ketamine and (R)-ketamine coadministered with LY341495 on the locomotor activity of mice. The values are expressed as the means ± SEM and were analyzed by repeated-measures ANOVA. **** p < 0.0001 vs. vehicle (N = 8).CC BY · PubMed Central
Figure 7 The effects of (R)-ketamine coadministered with LY341495 on BDNF levels in the CUMS model of depression. (A) effects in the PFC; (B) effects in the hippocampus; (C) effects in the plasma. The values are expressed as the means ± SEM and were analyzed by two-way ANOVA. @ p < 0.05 drug × drug interaction; ** p < 0.01 (CUMS effect, t test) (N = 8).
Figure 7 The effects of (R)-ketamine coadministered with LY341495 on BDNF levels in the CUMS model of depression. (A) effects in the PFC; (B) effects in the hippocampus; (C) effects in the plasma. The values are expressed as the means ± SEM and were analyzed by two-way ANOVA. @ p < 0.05 drug × drug interaction; ** p < 0.01 (CUMS effect, t test) (N = 8).CC BY · PubMed Central
Figure 8 The schedule of the CUMS experiments.
Figure 8 The schedule of the CUMS experiments.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 29

Metadata

Authors
Rafało-Ulińska, A., Brański, P., & Pałucha-Poniewiera, A.
Affiliations
Maj Institute of Pharmacology (PL)
Corresponding author
Pałucha-Poniewiera, Agnieszka
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2022-01-21
Volume
15
Issue
2
Pages
125
ISSN
1424-8247 (ISSN-L)
OpenAlex
W4207049519
Cited by
29
References
45
Citations by year
2026: 1 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 10
FWCI
4.19
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Science Center (2017/27/B/NZ7/01873)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
(R)-ketamine, LY341495, rapid-acting antidepressants, depression, chronic unpredictable mild stress, brain-derived neurotrophic factor, TrkB signaling, AMPA receptors, hippocampus, anhedonia, apathy, combination therapy, ketamine enantiomers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.